Origin Therapeutics Holdings Inc. announced that one of its portfolio companies, Xpira Pharmaceuticals, has obtained approval from the United States Food and Drug Administration ("FDA") for its first Investigational New Drug ("IND") application. Xpira Pharmaceuticals is a leader in the development of psychedelic medicines for the treatment of eating disorders, particularly for patients who have not responded well to conventional therapies. Following this week's announced FDA approval, Xpira will commence a Phase 2a clinical trial to study the efficacy of psilocybin-assisted therapy in patients diagnosed with the eating disorder Anorexia Nervosa.